Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: DVAX	
Last Trade:	5.55
Trade Time:	4:00 PM ET Apr 28, 2017
Change:	-0.10 (-1.770%)
Day Range	5.45 - 5.70
52-Week Range	3.20 - 17.50
Volume	617,313

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... (more)

Stock Performance

Press Releases [View all]

Apr 3, 2017
Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B

Mar 20, 2017
Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting

Mar 13, 2017
Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update

Mar 6, 2017
Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies

Mar 2, 2017
Dynavax to Present at the Cowen and Company 37th Annual Health Care Conference

Financials [View all]

Fourth Quarter Financial Results

Mar 13, 2017
Annual Report (10-K)

Apr 21, 2017
Proxy Statement (DEF 14A)

Nov 7, 2016
Quarterly Report (10-Q)

Aug 8, 2016
Quarterly Report (10-Q)

May 9, 2016
Quarterly Report (10-Q)